CC
ACAD icon

Clearline Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Clearline Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,812
Closed -$636K – 50
2017
Q2 		$636K Buy
22,812
+6,430
+39% +$192K 0.4% 33
2017
Q1 		$563K Buy
+16,382
New +$578K 0.27% 49

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Clearline Capital's ACAD Position: Q3 2017 in Review

Clearline Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 22,812 shares — an estimated $636K sold.

Clearline Capital first reported a position in ACAD in Q1 2017 and held it in 2 quarters. The position peaked at $636K in Q2 2017. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

  • Clearline Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Clearline Capital sold 22,812 Acadia Pharmaceuticals shares in Q3 2017, an estimated $636K.
  • Clearline Capital first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Clearline Capital's Acadia Pharmaceuticals position peaked at $636K in Q2 2017.
  • 212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on Clearline Capital's 13F filing for Q3 2017, filed 14 Nov 2017.